Merck (NYSE: MRK) reported Q4 EPS of $1.32, $0.06 worse than the analyst estimate of $1.38. Revenue for the quarter came in at $12.5 billion versus the consensus estimate of $12.68 billion.

GUIDANCE:

Merck sees FY2021 EPS of $6.48-$6.68, versus the consensus of $6.41. Merck sees FY2021 revenue of $51.8-53.8 billion, versus the consensus of $51.77 billion.

For earnings history and earnings-related data on Merck (MRK) click here.